Andrea Anichini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/46270/publications.pdf

Version: 2024-02-01

144 papers	9,055 citations	38742 50 h-index	45317 90 g-index
152 all docs	152 docs citations	152 times ranked	13488 citing authors

#	Article	IF	Citations
1	Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. Journal of Clinical Medicine, 2021, 10, 1741.	2.4	5
2	Heme catabolism by tumor-associated macrophages controls metastasis formation. Nature Immunology, 2021, 22, 595-606.	14.5	59
3	Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells. , 2021, 9, e002240.		4
4	Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma. Frontiers in Oncology, 2021, 11, 628324.	2.8	2
5	A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation. Journal of Experimental and Clinical Cancer Research, 2021, 40, 240.	8.6	3
6	Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma. Cancers, 2020, 12, 112.	3.7	30
7	Immune Escape Mechanisms in Non Small Cell Lung Cancer. Cancers, 2020, 12, 3605.	3.7	92
8	Improved Prognostic Prediction in Never-Smoker Lung Cancer Patients by Integration of a Systemic Inflammation Marker with Tumor Immune Contexture Analysis. Cancers, 2020, 12, 1828.	3.7	1
9	A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy. Frontiers in Immunology, 2019, 10, 2514.	4.8	7
10	An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells. Oncogene, 2019, 38, 4384-4396.	5.9	36
11	Microenvironment and tumor inflammatory features improve prognostic prediction in gastroâ€enteroâ€pancreatic neuroendocrine neoplasms. Journal of Pathology: Clinical Research, 2019, 5, 217-226.	3.0	29
12	Progress in Understanding Complexity and Determinants of Immune-Related Prognostic Subsets in Primary Melanoma. Cancer Research, 2019, 79, 2457-2459.	0.9	6
13	Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. Clinical Cancer Research, 2019, 25, 7351-7362.	7.0	61
14	Antibodyâ€“Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Nonâ€“small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clinical Cancer Research, 2019, 25, 989-999.	7.0	315
15	The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy. Cancer Immunology, Immunotherapy, 2018, 67, 1011-1022.	4.2	36
16	Of Chemoimmunotherapy Sequences and Delayed Disease-modifying Activity in Advanced Urothelial Carcinoma: Vetus Fit Novum. European Urology, 2018, 73, 153-155.	1.9	1
17	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. Journal of Clinical Oncology, 2018, 36, 3353-3360.	1.6	474
18	Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb. Journal of Experimental and Clinical Cancer Research, 2018, 37, 278.	8.6	19

#	Article	IF	Citations
19	Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. Targeted Oncology, 2018, 13, 567-582.	3.6	12
20	Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells. MAbs, 2018, 10, 1084-1097.	5.2	17
21	IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. Oncolmmunology, 2017, 6, e1261242.	4.6	59
22	Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Nonâ€“Small Cell Lung Cancer. Cancer Research, 2017, 77, 851-861.	0.9	49
23	Cancer Immunotherapy: from the lab to clinical applications. Potential impact on cancer centresâ€™ organisation. Ecancermedicalscience, 2016, 10, 691.	1.1	1
24	Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure. Clinical Genitourinary Cancer, 2016, 14, 261-264.e4.	1.9	22
25	HLA class I downregulation is associated with enhanced NKâ€cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. European Journal of Immunology, 2016, 46, 409-419.	2.9	31
26	NFATc2 is an intrinsic regulator of melanoma dedifferentiation. Oncogene, 2016, 35, 2862-2872.	5.9	43
27	Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. Oncotarget, 2016, 7, 3947-3965.	1.8	45
28	Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells. Oncotarget, 2015, 6, 2779-2793.	1.8	56
29	A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. Oncotarget, 2015, 6, 5118-5133.	1.8	37
30	Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma. Cell Death and Disease, 2014, 5, e1434-e1434.	6.3	20
31	Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. Clinical Cancer Research, 2014, 20, 5641-5651.	7.0	31
32	Enrichment of CD56dimKIR+CD57+ highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nature Communications, 2014, 5, 5639.	12.8	109
33	Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. Journal of Neuro-Oncology, 2014, 118, 305-312.	2.9	61
34	BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. Leukemia, 2014, 28, 1861-1871.	7.2	48
35	Prediction of Survival in Patients With Thin Melanoma: Results From a Multi-Institution Study. Journal of Clinical Oncology, 2014, 32, 2479-2485.	1.6	103
36	Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles. BMC Cancer, 2014, 14, 560.	2.6	30

#	Article	IF	Citations
37	Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review). International Journal of Oncology, 2014, 45, 929-949.	3.3	34
38	APAF-1 Signaling. , 2014, , 315-319.		0
39	Role of Macrophage Targeting in the Antitumor Activity of Trabectedin. Cancer Cell, 2013, 23, 249-262.	16.8	721
40	EGFR/MEK/ERK/CDK5-dependent integrin-independent FAK phosphorylated on serine 732 contributes to microtubule depolymerization and mitosis in tumor cells. Cell Death and Disease, 2013, 4, e815-e815.	6.3	39
41	Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts. Leukemia, 2013, 27, 1677-1687.	7.2	26
42	IGKV3 Proteins as Candidate â€œOff-the-Shelfâ€•Vaccines for Kappa-Light Chainâ€“Restricted B-Cell Non-Hodgkin Lymphomas. Clinical Cancer Research, 2012, 18, 4080-4091.	7.0	14
43	AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway. Melanoma Research, 2012, 22, 341-350.	1.2	38
44	Role of Apollon in Human Melanoma Resistance to Antitumor Agents That Activate the Intrinsic or the Extrinsic Apoptosis Pathways. Clinical Cancer Research, 2012, 18, 3316-3327.	7.0	27
45	NFATc2 Is a Potential Therapeutic Target in Human Melanoma. Journal of Investigative Dermatology, 2012, 132, 2652-2660.	0.7	41
46	Microfluidic Devices Modulate Tumor Cell Line Susceptibility to NK Cell Recognition. Small, 2012, 8, 2886-2894.	10.0	29
47	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. Journal of Molecular Medicine, 2012, 90, 667-679.	3.9	54
48	Phase <scp>II</scp> study of sorafenib in patients with relapsed or refractory lymphoma. British Journal of Haematology, 2012, 158, 108-119.	2.5	36
49	Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle, 2011, 10, 3346-3358.	2.6	93
50	T-Cell Activation and Maturation at Tumor Site Associated With Objective Response to Ipilimumab in Metastatic Melanoma. Journal of Clinical Oncology, 2011, 29, e783-e788.	1.6	8
51	Human Cutaneous Melanomas Lacking MITF and Melanocyte Differentiation Antigens Express a Functional Axl Receptor Kinase. Journal of Investigative Dermatology, 2011, 131, 2448-2457.	0.7	122
52	APAF-1 Signaling. , 2011, , 231-234.		0
53	Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors. Clinical Cancer Research, 2010, 16, 5862-5872.	7.0	56
54	Tumor-Reactive CD8+ Early Effector T Cells Identified at Tumor Site in Primary and Metastatic Melanoma. Cancer Research, 2010, 70, 8378-8387.	0.9	52

#	Article	IF	Citations
55	Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. British Journal of Cancer, 2010, 102, 1707-1716.	6.4	70
56	Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5. International Immunology, 2009, 21, 257-268.	4.0	25
57	Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells. Clinical Cancer Research, 2009, 15, 5852-5860.	7.0	120
58	Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage. Clinical Cancer Research, 2009, 15, 4085-4094.	7.0	29
59	Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients. Cancer Research, 2009, 69, 7338-7346.	0.9	157
60	Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations. Neoplasia, 2009, 11, 720-W6.	5.3	87
61	Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood, 2009, 113, 18-27.	1.4	99
62	NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. Journal of Clinical Investigation, 2009, 119, 1251-1263.	8.2	313
63	The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells. Haematologica, 2008, 93, 1523-1534.	3.5	63
64	Interleukin-12: Biological Properties and Clinical Application. Clinical Cancer Research, 2007, 13, 4677-4685.	7.0	517
65	Regulation of Breast Cancer Response to Chemotherapy by Fibulin-1. Cancer Research, 2007, 67, 4271-4277.	0.9	59
66	Artificial Antigen Presenting Cells With Preclustered anti-CD28/-CD3/-LFA-1 Monoclonal Antibodies Are Highly Effective To Induce The Ex-Vivo Expansion Of Functional Human Antitumor T Cells. Nature Precedings, 2007, , .	0.1	0
67	Targeting Heat Shock Proteins on Cancer Cells:Â Selection, Characterization, and Cell-Penetrating Properties of a Peptidic GRP78 Ligandâ€. Biochemistry, 2006, 45, 9434-9444.	2.5	172
68	APAF-1 signaling in human melanoma. Cancer Letters, 2006, 238, 168-179.	7.2	37
69	T cell infiltration and prognosis in HCC patients. Journal of Hepatology, 2006, 45, 178-181.	3.7	22
70	Skewed T-cell differentiation in patients with indolent non-Hodgkin lymphoma reversed by ex vivo T-cell culture with Î³c cytokines. Blood, 2006, 107, 602-609.	1.4	15
71	Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene, 2006, 25, 3357-3364.	5.9	157
72	Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cellâ€“Mediated Patient-Specific Immunotherapy. Clinical Cancer Research, 2006, 12, 5023-5032.	7.0	64

#	Article	IF	Citations
73	Association of Antigen-Processing Machinery and HLA Antigen Phenotype of Melanoma Cells with Survival in American Joint Committee on Cancer Stage III and IV Melanoma Patients. Cancer Research, 2006, 66, 6405-6411.	0.9	56
74	Coexpression of NRASQ61R and BRAFV600E in Human Melanoma Cells Activates Senescence and Increases Susceptibility to Cell-Mediated Cytotoxicity. Cancer Research, 2006, 66, 6503-6511.	0.9	81
75	HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine. Journal of Cellular Physiology, 2005, 205, 10-18.	4.1	30
76	Constitutive Expression and Costimulatory Function of LIGHT/TNFSF14 on Human Melanoma Cells and Melanoma-Derived Microvesicles. Cancer Research, 2005, 65, 3428-3436.	0.9	53
77	Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype. Cancer Research, 2005, 65, 632-40.	0.9	26
78	Apoptosis Protease Activator Protein-1 Expression Is Dispensable for Response of Human Melanoma Cells to Distinct Proapoptotic Agents. Cancer Research, 2004, 64, 7386-7394.	0.9	58
79	Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination. Clinical Cancer Research, 2004, 10, 5381-5390.	7.0	98
80	Immunological and pathobiological roles of fibulin-1 in breast cancer. Oncogene, 2004, 23, 2153-2160.	5.9	45
81	BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene, 2004, 23, 5968-5977.	5.9	189
82	The paradox of T cell?mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunology, Immunotherapy, 2004, 53, 855-64.	4.2	63
83	Immunotherapy of melanoma. Seminars in Cancer Biology, 2003, 13, 391-400.	9.6	48
84	Immunization of Patients with Malignant Melanoma with Autologous CD34+Cell-Derived Dendritic Cells TransducedEx Vivowith a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial. Human Gene Therapy, 2003, 14, 1347-1360.	2.7	22
85	Differentiation of CD8+ T Cells from Tumor-Invaded and Tumor-Free Lymph Nodes of Melanoma Patients: Role of Common Î³-Chain Cytokines. Journal of Immunology, 2003, 171, 2134-2141.	0.8	44
86	Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Research, 2003, 63, 2535-45.	0.9	142
87	Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection. Haematologica, 2003, 88, 1396-404.	3.5	11
88	Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?. Journal of the National Cancer Institute, 2002, 94, 805-818.	6.3	381
89	Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones. Tissue Antigens, 2002, 59, 273-279.	1.0	8
90	Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunological Reviews, 2002, 188, 97-113.	6.0	246

#	Article	IF	Citations
91	Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine. Cancer Gene Therapy, 2002, 9, 243-253.	4.6	12
92	Melanoma: The Milan Melanoma Cell Lines. , 2002, , 283-292.		1
93	Human Melanocytes and Melanomas Express Novel mRNA Isoforms of the Tyrosinase-Related Protein-2/DOPAchrome Tautomerase Gene: Molecular and Functional Characterization. Journal of Investigative Dermatology, 2000, 115, 48-56.	0.7	17
94	Stem Cells Research: Impact on Molecular Biology of Cancer and Prospects for Therapy of Neoplastic Diseases. Tumori, 2000, 86, 375-380.	1.1	0
95	Large-scale feasibility of gene transduction into human CD34+ cell-derived dendritic cells by adenoviral/polycation complex. British Journal of Haematology, 2000, 111, 344-350.	2.5	18
96	An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (Ctl)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific Ctls but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions. Journal of Experimental Medicine, 1999, 190, 651-668.	8.5	186
97	High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition. Cancer Immunology, Immunotherapy, 1999, 48, 39-46.	4.2	18
98	Translation of a Retained Intron in Tyrosinase-related Protein (TRP) 2 mRNA Generates a New Cytotoxic T Lymphocyte (CTL)-defined and Shared Human Melanoma Antigen Not Expressed in Normal Cells of the Melanocytic Lineage. Journal of Experimental Medicine, 1998, 188, 1005-1016.	8.5	131
99	Monocyte-derived dendritic cells and monocytes migrate to HIV-Tat RGD and basic peptides. Aids, 1998, 12, 261-268.	2.2	48
100	Intralesional Selection of T Cell Clonotypes in the Immune Response to Melanoma Antigens Occurring During Vaccination. Journal of Immunotherapy, 1998, 21, 198-204.	2.4	10
101	New tumour-restricted melanoma antigens as defined by cytotoxic T-cell responses. Melanoma Research, 1997, 7, S99.	1.2	8
102	Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine.. Journal of Clinical Investigation, 1997, 99, 710-717.	8.2	51
103	Expansion of Immunostimulatory Dendritic Cells from Peripheral Blood of Patients with Cancer. Oncologist, 1997, 2, 65-69.	3.7	5
104	Interaction with fibronectin regulates cytokine gene expression in human melanoma cells. , 1996, 66, 110-116.		14
105	Differential patterns ofHOX gene expression are associated with specific integrin and ICAM profiles in clonal populations isolated from a single human melanoma metastasis. , 1996, 66, 692-697.		45
106	Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 5674-5678.	7.1	95
107	The Î±3Î²1 Integrin Is Involved in Melanoma Cell Migration and Invasion. Experimental Cell Research, 1995, 219, 233-242.	2.6	126
108	Interleukin-Gene-Transduced Human Melanoma Cells Efficiently Stimulate MHC-Unrestricted and MHC-Restricted Autologous Lymphocytes. Human Gene Therapy, 1994, 5, 1139-1150.	2.7	44

#	Article	IF	Citations
109	Multiple sub-sets of Cd4+ and Cd8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles. International Journal of Cancer, 1994, 57, 56-62.	5.1	24
110	Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: Limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. International Journal of Cancer, 1994, 58, 330-339.	5.1	46
111	N-RAS mutations and susceptibility to lymphokine-activated killer (LAK) cells in human melanoma. Melanoma Research, 1994, 4, 11-19.	1.2	10
112	T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.. Journal of Experimental Medicine, 1993, 178, 1231-1246.	8.5	92
113	Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.. Journal of Experimental Medicine, 1993, 177, 989-998.	8.5	166
114	Tâ€cellâ€receptor engagement and tumor ICAMâ€1 upâ€regulation are required to byâ€pass low susceptibility of melanoma cells to autologous CTLâ€mediated lysis. International Journal of Cancer, 1993, 53, 994-1001.	5.1	33
115	??1-Integrins on Melanoma Clones Regulate the Interaction with Autologous Cytolytic T-Cell Clones. Journal of Immunotherapy, 1992, 12, 183-186.	2.4	8
116	Expansion of Major Histocompatibility Complex-Restricted Antimelanoma Cytotoxic T-Cell Lymphocyte Clones with Identical T-Cell Receptor from Tumor-Infiltrating Lymphocytes. Journal of Immunotherapy, 1992, 12, 207-211.	2.4	5
117	Use of the Vdelta1 Variable Region in the Functional T-Cell Receptor alpha Chain of a WT31+ Cytotoxic T Lymphocyte Clone which Specifically Recognizes HLA-A2 Molecule. Scandinavian Journal of Immunology, 1992, 35, 487-494.	2.7	9
118	Heterogeneous susceptibility of human melanoma clones to monocyte cytotoxicity: Role of ICAM-1 defined by antibody blocking and gene transfer. European Journal of Immunology, 1992, 22, 2255-2260.	2.9	30
119	Cell retargeting by bispecific monoclonal antibodies. Evidence of bypass of intratumor susceptibility to cell lysis in human melanoma.. Journal of Clinical Investigation, 1992, 90, 1093-1099.	8.2	15
120	Heterogeneity for integrin expression and cytokine-mediated VLA modulation can influence the adhesion of human melanoma cells to extracellular matrix proteins. International Journal of Cancer, 1991, 47, 551-559.	5.1	89
121	T lymphocytes can mediate lysis of autologous melanoma cells by multiple mechanisms: Evidence with a single T cell clone. Cancer Immunology, Immunotherapy, 1990, 32, 13-21.	4.2	17
122	Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. comparison with anti-proliferative activity by RIL1-Î², RTNF-Î±, RIFN-Î³, RIl4 and their combinations. International Journal of Cancer, 1990, 45, 334-341.	5.1	81
123	Human melanoma cells with high susceptibility to cell-mediated lysis can be identified on the basis of icam-1 phenotype, vla profile and invasive ability. International Journal of Cancer, 1990, 46, 508-515.	5.1	74
124	Cellular Immune Response Against Autologous Human Malignant Melanoma: Are In Vitro Studies Providing a Framework for a More Effective Immunotherapy?. Journal of the National Cancer Institute, 1990, 82, 361-370.	6.3	77
125	Gene transfer by retrovirus-derived shuttle vectors in the generation of murine bispecific monoclonal antibodies.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 2941-2945.	7.1	20
126	Multiple VLA antigens on a subset of melanoma clones. Human Immunology, 1990, 28, 119-122.	2.4	8

#	Article	IF	Citations
127	Immune response to specific human tumors. Current Opinion in Immunology, 1989, 1, 917-921.	5.5	3
128	Proliferative and/or cytotoxic activity of lymphocyte clones to autologous human melanoma. International Journal of Cancer, 1988, 42, 239-245.	5.1	17
129	Melanoma cell lysis by human CTL clones: Differential involvement of T3, T8 and HLA antigens. International Journal of Cancer, 1987, 39, 689-694.	5.1	13
130	Clonal analysis of the cytolytic T-cell response to human tumors. Trends in Immunology, 1987, 8, 385-389.	7.5	86
131	Phenotypic profile of clones from early cultures of human metastatic melanomas and its modulation by recombinant interferon Î³. International Journal of Cancer, 1986, 38, 505-511.	5.1	35
132	Heterogeneity of clones from a human metastatic melanoma detected by autologous cytotoxic T lymphocyte clones.. Journal of Experimental Medicine, 1986, 163, 215-220.	8.5	53
133	Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells. Cancer and Metastasis Reviews, 1985, 4, 7-26.	5.9	22
134	Clonal analysis of cytotoxic T-lymphocyte response to autologous human metastatic melanoma. International Journal of Cancer, 1985, 35, 683-689.	5.1	102
135	Inhibition of anti-class I cytotoxicity by anti-class II monoclonal antibodies (MoAb). II. Blocking of anti-class I CTL clones by anti-DR MoAb. Human Immunology, 1985, 13, 139-143.	2.4	11
136	Inhibition of Anti-class I cytotoxicity by anti-class II monoclonal antibodies (MoAb). I. Blocking of bulk non-DR and non-DQ-directed cytotoxic T cells by MoAb against DR, DO, and DP. Human Immunology, 1985, 13, 125-137.	2.4	6
137	Analysis of human class II antigens by cloned cytolytic T cell reagents: A study using HLA loss mutant lymphoblastoid cell lines and monoclonal antibodies detecting the HLA-DP product(s). Human Immunology, 1985, 13, 21-32.	2.4	12
138	HLA-Dw/LD directed cytotoxic T cell clones. Human Immunology, 1984, 10, 153-164.	2.4	7
139	Clonal analysis of T lymphocyte response to an isolated class I disparity. Human Immunology, 1983, 8, 195-206.	2.4	21
140	Genetic and molecular analyses of lymphocyte-defined HLA-D region specificities. Human Immunology, 1983, 8, 25-32.	2.4	8
141	A microcalorimetric study of the macrocyclic effect. Enthalpies of formation of copper(II) and zinc(II) complexes with some tetra-aza macrocyclic ligands in aqueous solution. Journal of the Chemical Society Dalton Transactions, 1978, , 577.	1.1	37
142	Thermodynamic and electronic and electron spin resonance spectroscopic investigation of the co-ordinating properties of 4-azaoctane-1,8-diamine (spermidine) in aqueous solution. Journal of the Chemical Society Dalton Transactions, 1977, , 2224.	1.1	13
143	Calorimetric determination of macrocyclic enthalpy. Copper(II) and zinc(II) complexes with 1,4,8,11-tetra-azacyclotetradecane. Journal of the Chemical Society Chemical Communications, 1977, , 244.	2.0	16
144	Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine. , 0, .		1